scholarly article | Q13442814 |
P50 | author | Anna Wald | Q41122225 |
Kathryn M. Edwards | Q52577914 | ||
Patricia L Winokur | Q56481179 | ||
Karen L Kotloff | Q63214788 | ||
Lisa A Jackson | Q97556689 | ||
Diana L. Noah | Q109940643 | ||
P2093 | author name string | Emmanuel B Walter | |
Mark Wolff | |||
Wilbur H Chen | |||
Pandemic H1N1 Vaccine Adult Study Group | |||
P2860 | cites work | Effectiveness of non-adjuvanted pandemic influenza A vaccines for preventing pandemic influenza acute respiratory illness visits in 4 U.S. communities | Q28741469 |
Immune response after a single vaccination against 2009 influenza A H1N1 in USA: a preliminary report of two randomised controlled phase 2 trials. | Q30227381 | ||
Response to a monovalent 2009 influenza A (H1N1) vaccine. | Q30380581 | ||
Safety and immunogenicity of 2009 pandemic influenza A H1N1 vaccines in China: a multicentre, double-blind, randomised, placebo-controlled trial. | Q30383576 | ||
Safety and immunogenicity of a 2009 pandemic influenza A H1N1 vaccine when administered alone or simultaneously with the seasonal influenza vaccine for the 2009-10 influenza season: a multicentre, randomised controlled trial. | Q30383579 | ||
An alternative method for preparation of pandemic influenza strain-specific antibody for vaccine potency determination. | Q30384418 | ||
The development of vaccine viruses against pandemic A(H1N1) influenza | Q30398053 | ||
Safety of influenza A (H1N1) vaccine in postmarketing surveillance in China | Q30399259 | ||
H1N1 and seasonal influenza vaccine safety in the vaccine safety datalink project | Q30404999 | ||
Effect of prior vaccination with a seasonal trivalent influenza vaccine on the antibody response to the influenza pandemic H1N1 2009 vaccine: a randomized controlled trial | Q30406785 | ||
Long-lasting immunogenicity and safety of a 2009 pandemic influenza A(H1N1) MF59-adjuvanted vaccine when co-administered with a 2009-2010 seasonal influenza vaccine in young patients with type 1 diabetes mellitus. | Q30407057 | ||
Response to 2009 pandemic and seasonal influenza vaccines co-administered to HIV-infected and HIV-uninfected former drug users living in a rehabilitation community in Italy | Q30407814 | ||
Reproducibility of serology assays for pandemic influenza H1N1: collaborative study to evaluate a candidate WHO International Standard | Q30409734 | ||
Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. | Q33974507 | ||
Licensure of a high-dose inactivated influenza vaccine for persons aged >or=65 years (Fluzone High-Dose) and guidance for use - United States, 2010. | Q34112980 | ||
Preliminary results: surveillance for Guillain-Barré syndrome after receipt of influenza A (H1N1) 2009 monovalent vaccine - United States, 2009-2010. | Q34118789 | ||
Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects | Q34697810 | ||
Antibody and Th1-type cell-mediated immune responses in elderly and young adults immunized with the standard or a high dose influenza vaccine | Q34761957 | ||
Randomized, double-blind controlled phase 3 trial comparing the immunogenicity of high-dose and standard-dose influenza vaccine in adults 65 years of age and older | Q38380921 | ||
A Single Dose of Unadjuvanted Novel 2009 H1N1 Vaccine Is Immunogenic and Well Tolerated in Young and Elderly Adults | Q38499447 | ||
Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses | Q40205161 | ||
Adverse events following influenza A (H1N1) 2009 monovalent vaccines reported to the Vaccine Adverse Event Reporting System, United States, October 1, 2009–January 31, 2010 | Q43152358 | ||
Detection of anti-H5 responses in human sera by HI using horse erythrocytes following MF59-adjuvanted influenza A/Duck/Singapore/97 vaccine | Q44910890 | ||
Safety and immunogenicity of an inactivated subvirion influenza A (H5N1) vaccine. | Q55041754 | ||
Safety of High Doses of Influenza Vaccine and Effect on Antibody Responses in Elderly Persons | Q56459658 | ||
P433 | issue | 28 | |
P407 | language of work or name | English | Q1860 |
P921 | main subject | emergency management | Q1460420 |
pandemic | Q12184 | ||
pandemic preparedness | Q88434121 | ||
P304 | page(s) | 4240-4248 | |
P577 | publication date | 2012-04-23 | |
P1433 | published in | Vaccine | Q7907941 |
P1476 | title | Phase 2 assessment of the safety and immunogenicity of two inactivated pandemic monovalent H1N1 vaccines in adults as a component of the U.S. pandemic preparedness plan in 2009. | |
P478 | volume | 30 |
Q91941716 | Age-associated changes in the impact of sex steroids on influenza vaccine responses in males and females |
Q30357144 | Antibody response to influenza A(H1N1)pdm09 among healthcare personnel receiving trivalent inactivated vaccine: effect of prior monovalent inactivated vaccine. |
Q30366806 | Clinical and immune responses to inactivated influenza A(H1N1)pdm09 vaccine in children. |
Q30362185 | Impact of body mass index on immunogenicity of pandemic H1N1 vaccine in children and adults. |
Q30352081 | Impact of human cytomegalovirus (CMV) infection on immune response to pandemic 2009 H1N1 influenza vaccine in healthy adults. |
Q30378668 | Low-dose aspirin use does not diminish the immune response to monovalent H1N1 influenza vaccine in older adults |
Q49587964 | Negative Effect of Age, but Not of Latent Cytomegalovirus Infection on the Antibody Response to a Novel Influenza Vaccine Strain in Healthy Adults |
Q30369098 | Phase II trial in adults of concurrent or sequential 2009 pandemic H1N1 and 2009-2010 seasonal trivalent influenza vaccinations |
Q30204573 | Point-of-Use Mixing of Influenza H5N1 Vaccine and MF59 Adjuvant for Pandemic Vaccination Preparedness: Antibody Responses and Safety. A Phase 1 Clinical Trial |
Q30371419 | Safety and Immunogenicity of a Subvirion Monovalent Unadjuvanted Inactivated Influenza A(H3N2) Variant Vaccine in Healthy Persons ≥18 Years Old |
Q58566464 | Safety and immunogenicity of inactivated monovalent influenza A/H1N1 vaccine candidate manufactured in Vietnam |
Q30204578 | Safety, Reactogenicity, and Immunogenicity of Inactivated Monovalent Influenza A(H5N1) Virus Vaccine Administered With or Without AS03 Adjuvant |
Search more.